Education
About Us
Working with TipRanks
Follow Us
Medite Cancer Diagnostics (MDIT)
:MDIT
MDIT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.01 - $0.01
Previous CloseN/A
Volume25.00
Average Volume (3M)1.92K
Market Cap
$8.62K
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta33.10
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding86,196,700
10 Day Avg. Volume1,918
30 Day Avg. Volume1,918
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
MDIT FAQ
What was Medite Cancer Diagnostics ’s price range in the past 12 months?
Medite Cancer Diagnostics lowest stock price was $0.01 and its highest was $0.01 in the past 12 months.
What is Medite Cancer Diagnostics ’s market cap?
Medite Cancer Diagnostics ’s market cap is $8.62K.
When is Medite Cancer Diagnostics ’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Medite Cancer Diagnostics ’s earnings last quarter?
Medite Cancer Diagnostics released its earnings results on Aug 14, 2017. The company reported -$0.06 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.06.
Is Medite Cancer Diagnostics overvalued?
According to Wall Street analysts Medite Cancer Diagnostics ’s price is currently Overvalued.
Does Medite Cancer Diagnostics pay dividends?
Medite Cancer Diagnostics does not currently pay dividends.
What is Medite Cancer Diagnostics ’s EPS estimate?
Medite Cancer Diagnostics ’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Medite Cancer Diagnostics have?
Medite Cancer Diagnostics has 86,196,700 shares outstanding.
What happened to Medite Cancer Diagnostics ’s price movement after its last earnings report?
Medite Cancer Diagnostics reported an EPS of -$0.06 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Medite Cancer Diagnostics ?
Currently, no hedge funds are holding shares in MDIT
Company Description
Medite Cancer Diagnostics
Medite Cancer Diagnostics, Inc. operates as a medical technology company. It develops, manufactures, and markets molecular biomarkers, medical devices, and consumables for the detection, risk assessment, and diagnosis of cancerous and precancerous conditions and related diseases. The company offers USE 33, an ultrasonic decalcification instrument that automatically runs the process under controlled temperatures; TPC 15 Duo and Trio, a tissue processing instrument; TES 99 and TES Valida cooling units; and M530, A550, M380 microtomes for tissue sectioning. It also provides M630, a freezing microtome; TST44, a robotic multi-staining system; COT 20, a linear staining system; and RCM 9000, ACS 720, and TWISTER robotic coverslippers. In addition, the company develops SoftKit device for the self-collection of a sample that can be evaluated to provide an assessment of the health of the entire female genital tract. It sells its products through direct sales and distributors in the United States, China, Europe, and North Africa. The company serves histology and cytology laboratories associated with hospitals or research institutions, and independent laboratories. Medite Cancer Diagnostics, Inc. is based in Orlando, Florida.
Technical Analysis
Biodexa Pharmaceuticals
―
Hepion Pharmaceuticals
―
Windtree Therapeutics
―
Onconetix
―
Sharps Technology, Inc.
―